stockrowGuardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) Net income
Guardant Health, Inc.'s net income for fiscal 2025 was −$416.3M, compared with −$436.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$485.1M. Over the past ten years it has ranged from −$654.6M (fiscal 2022) to −$46.1M (fiscal 2016); the current reading is higher than 40% of that period. Net income has risen for 3 consecutive fiscal years. Guardant Health, Inc. ranks 49th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$416.3M | — |
| FY2024 | −$436.4M | — |
| FY2023 | −$479.4M | — |
| FY2022 | −$654.6M | — |
| FY2021 | −$384.8M | — |
| FY2020 | −$246.3M | — |
| FY2019 | −$67.9M | — |
| FY2018 | −$84.3M | — |
| FY2017 | −$83.2M | — |
| FY2016 | −$46.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$124.4M | — |
| Jun 2026 | −$120.1M | — |
| Mar 2026 | −$112.1M | — |
| Dec 2025 | −$128.5M | — |
| 34 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. compare | $895.0M |
| MEDP Medpace Holdings, Inc. compare | $517.8M |
| ICLR ICON PLC compare | $448.7M |
| RVTY Revvity Inc. compare | $253.2M |
| CRL Charles River Laboratories International, Inc. compare | $42.6M |
| GH Guardant Health, Inc. | −$485.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on GH
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement